Mechanism of Action: Potassium Channel Antagonists
✉ Email this page to a colleague
Drugs with Mechanism of Action: Potassium Channel Antagonists
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merz Pharms | AMPYRA | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 022250-001 | Jan 22, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sun Pharm | DALFAMPRIDINE | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 208292-001 | May 21, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Alkem Labs Ltd | DALFAMPRIDINE | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 206765-001 | Jul 30, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Accord Hlthcare | DALFAMPRIDINE | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 206863-001 | Jul 11, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Aurobindo Pharma | DALFAMPRIDINE | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 206811-001 | Jan 23, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Actavis Labs Fl Inc | DALFAMPRIDINE | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 206836-001 | Jan 23, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
